Zacks Research Upgrades Curis (NASDAQ:CRIS) to Hold

Curis (NASDAQ:CRIS) was upgraded by analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a research note issued on Wednesday, Zacks reports.

Other equities research analysts have also recently issued research reports about the company. HC Wainwright reissued a “buy” rating on shares of Curis in a research note on Monday, August 17th. Wall Street Zen raised Curis from a “strong sell” rating to a “hold” rating in a research report on Saturday, August 22nd. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Curis in a report on Friday, July 17th. One research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average target price of $43.00.

Curis Trading Down 3.3%

CRIS opened at $1.16 on Wednesday. The company has a market cap of $2.42 million, a P/E ratio of -0.08 and a beta of 3.01. The company has a fifty day moving average price of $3.35 and a two-hundred day moving average price of $9.20. Curis has a 1-year low of $1.11 and a 1-year high of $39.00.

Curis (NASDAQ:CRIS) last issued its earnings results on Friday, August 14th. The biotechnology company reported ($4.02) EPS for the quarter, beating the consensus estimate of ($6.95) by $2.93. Curis had a negative return on equity of 2,365.94% and a negative net margin of 80.29%. On average, research analysts forecast that Curis will post -24.23 EPS for the current fiscal year.

Hedge Funds Weigh In On Curis

Large investors have recently added to or reduced their stakes in the business. Jane Street Group LLC boosted its stake in Curis by 71.8% during the 4th quarter. Jane Street Group LLC now owns 25,323 shares of the biotechnology company’s stock valued at $25,000 after purchasing an additional 10,586 shares during the last quarter. XTX Topco Ltd purchased a new stake in shares of Curis in the fourth quarter worth approximately $26,000. Focused Wealth Management Inc bought a new position in shares of Curis in the second quarter valued at approximately $26,000. BlackRock Inc. bought a new position in shares of Curis in the second quarter valued at approximately $28,000. Finally, Squarepoint Ops LLC boosted its position in shares of Curis by 17.9% during the third quarter. Squarepoint Ops LLC now owns 59,140 shares of the biotechnology company’s stock valued at $98,000 after buying an additional 8,973 shares during the last quarter. Institutional investors own 29.97% of the company’s stock.

Curis Company Profile

Curis, Inc is a biotechnology company focused on the discovery, development and commercialization of targeted small molecule and antibody therapeutics for the treatment of cancer. The company’s research centers on exploiting key signaling pathways and tumor microenvironment interactions to develop compounds with the potential to address unmet medical needs. Curis’ proprietary pipeline includes multiple programs at various stages of clinical and preclinical development, reflecting its emphasis on innovative oncology drug candidates.

Among Curis’ lead assets is CA-4948, an oral inhibitor of interleukin-1 receptor–associated kinase 4 (IRAK4) partnered with Ikena Oncology, which is being evaluated in hematologic malignancies and solid tumors.